BD Group B Streptococcus Assay Gets 'Moderate Complexity' Status | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received "Moderate Complexity" status from the US Food and Drug Administration for its BD Max GBS Assay for Group B Streptococcus on the BD Max System, which could hasten molecular testing for the disease.

FDA granted "Moderate Complexity" to the assay under CLIA regulations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.